Drug intelligence / Profile preview

HMBD-803

Development stage: Preclinical
Lead developer: Callio Therapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

HMBD-803 is an **antibody-drug conjugate (ADC)** developed by Hummingbird Bioscience Pte Ltd. and currently licensed to Callio Therapeutics. It is in the **preclinical** phase of development. The drug targets an undisclosed antigen and is designed to trigger target internalization. It employs a dual-payload strategy, which is a recent trend in ADC development aimed at overcoming payload resistance.

Beyond the preview

Go deeper on HMBD-803.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HMBD-803.

Explore the full profile